Workflow
Bullfrog AI (BFRG)
icon
Search documents
Join Bullfrog AI's Exclusive Live Investor Webinar and Q&A Session on April 23
Newsfilter· 2025-04-17 12:00
GAITHERSBURG, Md., April 17, 2025 (GLOBE NEWSWIRE) -- Bullfrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on April 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Vin Singh, CEO of Bullfrog AI. Attendees will gain insight ...
Join Bullfrog AI’s Exclusive Live Investor Webinar and Q&A Session on April 23
GlobeNewswire· 2025-04-17 12:00
GAITHERSBURG, Md., April 17, 2025 (GLOBE NEWSWIRE) -- Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on April 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Vin Singh, CEO of Bullfrog AI. Attendees will gain insight ...
Bullfrog AI (BFRG) - 2024 Q4 - Annual Report
2025-03-14 20:10
For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-41600 BULLFROG AI HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...
BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial
GlobeNewswire· 2025-02-27 13:00
Eleison to leverage BullFrog Data Networks™ to enhance patient clustering and safety analysis in glufosfamide clinical trialsGAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmace ...
BullFrog AI to Present at Biotech Showcase and RESI JPM During JP Morgan Week
GlobeNewswire· 2025-01-10 13:00
GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its participation in the TechBio track at Biotech Showcase and RESI JPM, both taking place during the annual JP Morgan Healthcare Conference in San Francisco, January 13–16, 2025. At both ...
BullFrog AI Issues Letter to Stockholders
GlobeNewswire· 2024-12-27 13:00
GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission ...
BullFrog AI Announces Appointment of Chief Financial Officer
Newsfilter· 2024-12-17 21:30
GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's forme ...
Bullfrog AI (BFRG) - 2024 Q3 - Quarterly Report
2024-11-08 22:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to Commission File Number 001-41600 BULLFROG AI HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 84-4786155 (State or other j ...
BullFrog AI's VP Artificial Intelligence to Present at Google's Cancer AI Symposium
GlobeNewswire News Room· 2024-10-22 11:30
GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google’s inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts. Dr. García-Rivera’s pre ...
WallachBeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
Prnewswire· 2024-10-21 17:00
JERSEY CITY, N.J., Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purch ...